| 产品编号 | bs-9474R-AF555 |
| 英文名称 | Anti-phospho-NFAT5 (Ser1197)/AF555 |
| 中文名称 | AF555标记的磷酸化活化T细胞核因子5蛋白抗体 |
| 别 名 | NFAT5 (phospho S1197); p-NFAT5(phospho S1197); Glutamine rich protein H65; KIAA0827; NF AT5; NF-AT5; NFAT 5; NFAT L1; NFAT like protein 1; NFAT5; NFAT5_HUMAN; NFATL 1; NFATL1; NFATZ; Nuclear factor of activated T cells 5; Nuclear factor of activated T cells 5 tonicity responsive; Nuclear factor of activated T cells; Nuclear factor of activated T-cells 5; OREBP; Osmotic response element binding protein; T cell transcription factor NFAT 5; T cell transcription factor NFAT5; T-cell transcription factor NFAT5; TonE binding protein; TonE-binding protein ; TonEBP; Tonicity responsive enhancer binding protein; Tonicity-responsive enhancer-binding protein. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 心血管 转录调节因子 淋巴细胞 t-淋巴细胞 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, ) |
| 产品应用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 166kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human NFAT5 around the phosphorylation site of Ser1197 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 |
background: Members of the NFAT (nuclear factor of activated T cells) family of transcription factors are related to NFkB/Rel proteins and form cooperative complexes with the AP-1 proteins, Fos and Jun, on DNA to regulate cytokine expression in T cells. NFAT proteins are widely expressed and alternatively modified to generate splice variants, and they are localized to both the cytosol (NFATc) and to the nucleus (NFATn). NFAT1, NFAT2, and NFAT4 are predominantly expressed in immune cells, and NFAT2 and NFAT3 are expressed at high levels in cardiac tissues. In addition to activating cytokine gene transcription, NFAT2 is also implicated in cardiac valve development, and NFAT3 is involved in cardiac hypertrophy. NFAT5 is detected in both immune and nonimmune cells and, like other NFAT proteins, contains a highly conserved Rel-like binding domain that mediates NFAT proteins associating with specific consensus sequences on DNA. NFAT proteins are activated by increases in intracellular calcium, which leads to the calmodulin-dependent phosphatase, calcineurin, dephosphorylating NFAT proteins. This activating event induces a conformational change in the protein structure that exposes the nuclear localization signal and facilitates the translocation of NFAT proteins from the cytosol into the nucleus. Function: Plays a role in the inducible expression of genes.Regulates hypertonicity-induced cellular accumulation of osmolytes. Subunit: Homodimer when bound to DNA, completely encircles its DNAtarget. Does not bind with Fos and Jun transcription factors. Subcellular Location: Nucleus. Tissue Specificity: Highest levels in skeletal muscle, brain, heart and peripheral blood leukocytes. Also expressed in placenta, lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine and colon. Post-translational modifications: Phosphorylated at Thr-135 by CDK5 in response to osmoticstress; this phosphorylation mediates its rapid nuclearlocalization. Similarity: Contains 1 RHD (Rel-like) domain. Database links: Entrez Gene: 10725 Human Entrez Gene: 54446 Mouse Omim: 604708 Human SwissProt: O94916 Human SwissProt: Q9WV30 Mouse Unigene: 371987 Human Unigene: 390057 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
